Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.
Standard
Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. / Spiro, Alexander Simon; Babin, Kornelia; Lipovac, S; Stenger, P; Mladenov, K; Rupprecht, Martin; Rueger, Johannes Maria; Stücker, Ralf.
in: J BONE JOINT SURG BR, Jahrgang 93, Nr. 5, 5, 2011, S. 695-699.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.
AU - Spiro, Alexander Simon
AU - Babin, Kornelia
AU - Lipovac, S
AU - Stenger, P
AU - Mladenov, K
AU - Rupprecht, Martin
AU - Rueger, Johannes Maria
AU - Stücker, Ralf
PY - 2011
Y1 - 2011
N2 - The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the treatment of congenital pseudarthrosis of the tibia has been investigated in only one previous study, with promising results. The aim of this study was to determine whether rhBMP-2 might improve the outcome of this disorder. We reviewed the medical records of five patients with a mean age of 7.4 years (2.3 to 21) with congenital pseudarthrosis of the tibia who had been treated with rhBMP-2 and intramedullary rodding. Ilizarov external fixation was also used in four of these patients. Radiological union of the pseudarthrosis was evident in all of them at a mean of 3.5 months (3.2 to 4) post-operatively. The Ilizarov device was removed after a mean of 4.2 months (3.0 to 5.3). These results indicate that treatment of congenital pseudarthrosis of the tibia using rhBMP-2 in combination with intramedullary stabilisation and Ilizarov external fixation may improve the initial rate of union and reduce the time to union. Further studies with more patients and longer follow-up are necessary to determine whether this surgial procedure may significantly enhance the outcome of congenital pseudarthrosis of the tibia, considering the refracture rate (two of five patients) in this small case series.
AB - The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the treatment of congenital pseudarthrosis of the tibia has been investigated in only one previous study, with promising results. The aim of this study was to determine whether rhBMP-2 might improve the outcome of this disorder. We reviewed the medical records of five patients with a mean age of 7.4 years (2.3 to 21) with congenital pseudarthrosis of the tibia who had been treated with rhBMP-2 and intramedullary rodding. Ilizarov external fixation was also used in four of these patients. Radiological union of the pseudarthrosis was evident in all of them at a mean of 3.5 months (3.2 to 4) post-operatively. The Ilizarov device was removed after a mean of 4.2 months (3.0 to 5.3). These results indicate that treatment of congenital pseudarthrosis of the tibia using rhBMP-2 in combination with intramedullary stabilisation and Ilizarov external fixation may improve the initial rate of union and reduce the time to union. Further studies with more patients and longer follow-up are necessary to determine whether this surgial procedure may significantly enhance the outcome of congenital pseudarthrosis of the tibia, considering the refracture rate (two of five patients) in this small case series.
KW - Humans
KW - Male
KW - Female
KW - Young Adult
KW - Treatment Outcome
KW - Follow-Up Studies
KW - Combined Modality Therapy
KW - Child, Preschool
KW - Retrospective Studies
KW - Ankle Joint/physiopathology
KW - Bone Morphogenetic Protein 2
KW - Bone Morphogenetic Proteins/therapeutic use
KW - External Fixators
KW - Fracture Fixation, Intramedullary/methods
KW - Fracture Healing/drug effects
KW - Ilizarov Technique
KW - Knee Joint/physiopathology
KW - Pseudarthrosis/congenital/drug therapy/radiography/surgery
KW - Range of Motion, Articular
KW - Recombinant Proteins/therapeutic use
KW - Tibial Fractures/drug therapy/radiography/surgery
KW - Transforming Growth Factor beta/therapeutic use
KW - Humans
KW - Male
KW - Female
KW - Young Adult
KW - Treatment Outcome
KW - Follow-Up Studies
KW - Combined Modality Therapy
KW - Child, Preschool
KW - Retrospective Studies
KW - Ankle Joint/physiopathology
KW - Bone Morphogenetic Protein 2
KW - Bone Morphogenetic Proteins/therapeutic use
KW - External Fixators
KW - Fracture Fixation, Intramedullary/methods
KW - Fracture Healing/drug effects
KW - Ilizarov Technique
KW - Knee Joint/physiopathology
KW - Pseudarthrosis/congenital/drug therapy/radiography/surgery
KW - Range of Motion, Articular
KW - Recombinant Proteins/therapeutic use
KW - Tibial Fractures/drug therapy/radiography/surgery
KW - Transforming Growth Factor beta/therapeutic use
M3 - SCORING: Journal article
VL - 93
SP - 695
EP - 699
IS - 5
M1 - 5
ER -